Cell & Gene Therapy

Join leaders, experts, and researchers connecting global academic & research organizations as well as pharma representatives for high-level discussions on the latest innovations in spatial research & technologies. Forward looking visionary leaders will discuss the current state of the industry, market trends and future growth areas aiding the application of spatial technologies in the clinic as well as the rise of digital pathology.

2-day event focusing on the latest innovations in spatial research & profiling as well as the latest developments in pushing spatial technologies to the clinic. Bringing together leaders in spatial biologics, technologies, profiling and bioinformatics.

Immuno-Oncology (IO) 360° takes a strategic look at the business and scientific aspects of Immuno-Oncology.  With significant in-put from Lead Advisors Dr. Axel Hoos (former CEO of Scorpion Therapeutics) and Dr. James Gulley (NCI,) the conference examines the current landscape, and reports on the latest advancements in IO to improve and accelerate clinical trials. The audience is comprised of roughly 500 top executives at Pharma companies and Biotechs, as well as the financial community, consultants and leading research organizations in the field of Immuno-Oncology.  

The Gene Therapy for Ophthalmic Disorders meeting is bringing you even more world class content, bringing you two tracks of learning to tackle the pressing challenges faced in the pre-clinical stages and in clinical development. This includes challenges faces with drug targets including wet AMD, dry AMD, DME, IRDs and more.

Keynotion Global Bioprocessing Summit brings together leading bioprocessing scientists and engineers to share day-to-day challenges and practical solutions for the development, manufacturing and quality of antibodies, vaccines and gene therapies. This world class conference is a mixture of Comprehensive Workshop, detailed case studies and interactive discussions in cell culture, scale-up, continuous Biomanufacturing, recovery, purification, process and product characterization, and formulation.

Returning in 2022, the Tumor Myeloid-Directed Therapeutics Summit is the only industry-focused meeting dedicated to unlocking novel therapeutic potential through the myeloid compartment.  This is your ultimate forum to identify, validate, and clinically progress myeloid targets to expand the oncologists toolkit and realize better responses by engaging myeloid anti-tumor function. Designed for experts working directly on myeloid-directed therapies, and those in adjacent immuno-oncology fields, from cell therapy to checkpoint and engager development. If you’re scratching your head in attempt to enhance efficacy in solid tumors and overcome barriers in the microenvironment, this is your 500-foot view of the intricate pathways, interactions, and novel target development in the tumor microenvironment. Deep-dive into myeloid biology, guided by 27+ industry Gurus from the likes of Pionyr Immunotherapeutics, Gilead Sciences, Merck, Verseau Therapeutics, Carisma Therapeutics, Pfizer and many more. With targets such as TREM1 and TREM2 making waves in the clinic, analysis of CD47 candidates back-translating to next-generation therapies, and novel dendritic cell candidates such as FTL3 in development, this 3-day myeloid extravaganza is unmissable for anyone looking to unlock better therapeutic potential through the myeloid compartment.

As Biopharma turn their focus to autoimmune drug development, there has been an explosion of interest and investment into Treg directed therapies. Promising proof-of-concept data and early clinical read outs have fueled further hype, and the industry now looks to demonstrate efficacy. The 4th Treg Directed Therapies Summit returns to Boston this May, bigger and better than ever before, boasting 2 tracks of unparalleled content to cater to cell-based, and non-cell-based experts alike. This is the only industry-focused meeting designed to bridge the gap between early discovery through clinical development of cell-based and non cell-based Treg directed therapies to provide efficacious treatments for patients globally. With 3 days of unrivalled content spanning the fundamental biology of Tregs, optimizing early drug development, and streamlining clinical development, join with your team to:Optimize stable expansion of Tregs to maintain function to elicit durable responses
Decode Treg interactions to optimize the mechanism of actions and inform biomarker development
Rationalize activation, formulation & delivery strategy to induce antigen specific tolerance
Supercharge CMC strategy to drive the modulation of antigen-specific responses to yield maximum clinical efficacy

From preclinical conversations to the latest developments in streamlined manufacturing this year’s meeting will be the most comprehensive guide for addressing the unique challenges of TIL development to bolster and strengthen your pipelines to achieve your 2022/23 milestones. With 20+ world-class speakers and over 100 senior attendees from around the globe, join the largest community of TIL-targeted drug development experts for a deep dive into clinical development progress, lessons learnt and novel strategies to maximize TIL-targeting to recognize and capitalize on this outstanding approach in adoptive cell therapy! Now is the time to leverage actionable insights to ensure you are set to capitalize on this achieve significant expansion in your development.

CPhI North America is the only pharma event in the US that covers the full supply chain, from research and manufacturing to packaging and finished products. We unite buyers and suppliers from around the globe for 2 days of networking, education and innovation, in Philadelphia, PA, the U.S pharma hub.